AG˹ٷ

STOCK TITAN

[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Praxis Precision Medicines, Inc. (PRAX) reported a routine insider equity award through a Form 4 filed on 27 June 2025. Director Jeffrey Chodakewitz received a grant of 10,520 stock options on 26 June 2025 at an exercise price of $44.04 per share. The options vest in 12 equal monthly installments over one year beginning the grant date and carry an expiration date of 26 June 2035. No open-market purchases or sales of common stock were disclosed, and Mr. Chodakewitz’s direct derivative holdings after the transaction total 10,520 options. The filing reflects a standard compensation-related award rather than a change in the director’s economic exposure to outstanding common shares.

Praxis Precision Medicines, Inc. (PRAX) ha comunicato un premio azionario interno di routine tramite un modulo Form 4 depositato il 27 giugno 2025. Il direttore Jeffrey Chodakewitz ha ricevuto una concessione di 10.520 opzioni su azioni il 26 giugno 2025 con un prezzo di esercizio di 44,04 $ per azione. Le opzioni maturano in 12 rate mensili uguali nell'arco di un anno a partire dalla data di concessione e scadono il 26 giugno 2035. Non sono stati segnalati acquisti o vendite sul mercato aperto di azioni ordinarie, e le partecipazioni derivate dirette del signor Chodakewitz dopo la transazione ammontano a 10.520 opzioni. La comunicazione riflette un premio standard legato alla compensazione e non un cambiamento nell'esposizione economica del direttore sulle azioni ordinarie in circolazione.

Praxis Precision Medicines, Inc. (PRAX) informó una adjudicación rutinaria de acciones internas a través de un Formulario 4 presentado el 27 de junio de 2025. El director Jeffrey Chodakewitz recibió una concesión de 10,520 opciones sobre acciones el 26 de junio de 2025 con un precio de ejercicio de $44.04 por acción. Las opciones se consolidan en 12 cuotas mensuales iguales durante un año a partir de la fecha de concesión y vencen el 26 de junio de 2035. No se revelaron compras o ventas en el mercado abierto de acciones comunes, y las participaciones derivadas directas del Sr. Chodakewitz después de la transacción suman 10,520 opciones. La presentación refleja una adjudicación estándar relacionada con la compensación en lugar de un cambio en la exposición económica del director a las acciones comunes en circulación.

Praxis Precision Medicines, Inc. (PRAX)� 2025� 6� 27� 제출� Form 4� 통해 정기 내부� 주식 보상� 보고했습니다. 이사 Jeffrey Chodakewitz� 2025� 6� 26� 주당 $44.04� 행사가격으� 10,520� 스톡 옵션� 부여받았습니다. � 옵션은 부여일로부� 1년간 매달 12회에 걸쳐 균등하게 권리가 확정되며, 만료일은 2035� 6� 26일입니다. 공개 시장에서� 보통� 매매� 없었으며, 거래 � Chodakewitz 이사� 직접 파생 보유량은 � 10,520 옵션입니�. 이번 보고� 이사� 경제� 노출 변동이 아닌 표준 보상 관� 보상임을 반영합니�.

Praxis Precision Medicines, Inc. (PRAX) a déclaré une attribution d'actions interne de routine via un formulaire Form 4 déposé le 27 juin 2025. Le directeur Jeffrey Chodakewitz a reçu une attribution de 10 520 options d'achat d'actions le 26 juin 2025 à un prix d'exercice de 44,04 $ par action. Les options se consolident en 12 versements mensuels égaux sur un an à compter de la date d'attribution et expirent le 26 juin 2035. Aucun achat ou vente d'actions ordinaires sur le marché ouvert n'a été divulgué, et les participations dérivées directes de M. Chodakewitz après la transaction s'élèvent à 10 520 options. Le dépôt reflète une attribution standard liée à la rémunération plutôt qu'un changement dans l'exposition économique du directeur aux actions ordinaires en circulation.

Praxis Precision Medicines, Inc. (PRAX) meldete eine routinemäßige Insider-Aktienzuteilung durch ein am 27. Juni 2025 eingereichtes Formular 4. Direktor Jeffrey Chodakewitz erhielt am 26. Juni 2025 eine Zuteilung von 10.520 Aktienoptionen zum Ausübungspreis von 44,04 $ pro Aktie. Die Optionen werden in 12 gleichen monatlichen Raten über ein Jahr ab dem Zuteilungsdatum unverfallbar und laufen am 26. Juni 2035 ab. Es wurden keine Käufe oder Verkäufe von Stammaktien am offenen Markt gemeldet, und Herr Chodakewitz hält nach der Transaktion insgesamt 10.520 Optionen. Die Meldung stellt eine standardmäßige, vergütungsbezogene Zuteilung dar und keine Änderung der wirtschaftlichen Beteiligung des Direktors an den ausstehenden Stammaktien.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine option grant to director; no immediate share movement; neutral impact.

The Form 4 discloses a typical annual equity incentive: 10,520 options granted to Director Jeffrey Chodakewitz at $44.04, vesting monthly over 12 months and expiring in 2035. Because the transaction is an award (code “A�) and involves derivatives rather than common stock, it does not alter the public float or signal insider sentiment through buying/selling. Such grants are common for biotech boards and are unlikely to sway valuation or liquidity. Investors should view the filing as administrative rather than a catalyst.

Praxis Precision Medicines, Inc. (PRAX) ha comunicato un premio azionario interno di routine tramite un modulo Form 4 depositato il 27 giugno 2025. Il direttore Jeffrey Chodakewitz ha ricevuto una concessione di 10.520 opzioni su azioni il 26 giugno 2025 con un prezzo di esercizio di 44,04 $ per azione. Le opzioni maturano in 12 rate mensili uguali nell'arco di un anno a partire dalla data di concessione e scadono il 26 giugno 2035. Non sono stati segnalati acquisti o vendite sul mercato aperto di azioni ordinarie, e le partecipazioni derivate dirette del signor Chodakewitz dopo la transazione ammontano a 10.520 opzioni. La comunicazione riflette un premio standard legato alla compensazione e non un cambiamento nell'esposizione economica del direttore sulle azioni ordinarie in circolazione.

Praxis Precision Medicines, Inc. (PRAX) informó una adjudicación rutinaria de acciones internas a través de un Formulario 4 presentado el 27 de junio de 2025. El director Jeffrey Chodakewitz recibió una concesión de 10,520 opciones sobre acciones el 26 de junio de 2025 con un precio de ejercicio de $44.04 por acción. Las opciones se consolidan en 12 cuotas mensuales iguales durante un año a partir de la fecha de concesión y vencen el 26 de junio de 2035. No se revelaron compras o ventas en el mercado abierto de acciones comunes, y las participaciones derivadas directas del Sr. Chodakewitz después de la transacción suman 10,520 opciones. La presentación refleja una adjudicación estándar relacionada con la compensación en lugar de un cambio en la exposición económica del director a las acciones comunes en circulación.

Praxis Precision Medicines, Inc. (PRAX)� 2025� 6� 27� 제출� Form 4� 통해 정기 내부� 주식 보상� 보고했습니다. 이사 Jeffrey Chodakewitz� 2025� 6� 26� 주당 $44.04� 행사가격으� 10,520� 스톡 옵션� 부여받았습니다. � 옵션은 부여일로부� 1년간 매달 12회에 걸쳐 균등하게 권리가 확정되며, 만료일은 2035� 6� 26일입니다. 공개 시장에서� 보통� 매매� 없었으며, 거래 � Chodakewitz 이사� 직접 파생 보유량은 � 10,520 옵션입니�. 이번 보고� 이사� 경제� 노출 변동이 아닌 표준 보상 관� 보상임을 반영합니�.

Praxis Precision Medicines, Inc. (PRAX) a déclaré une attribution d'actions interne de routine via un formulaire Form 4 déposé le 27 juin 2025. Le directeur Jeffrey Chodakewitz a reçu une attribution de 10 520 options d'achat d'actions le 26 juin 2025 à un prix d'exercice de 44,04 $ par action. Les options se consolident en 12 versements mensuels égaux sur un an à compter de la date d'attribution et expirent le 26 juin 2035. Aucun achat ou vente d'actions ordinaires sur le marché ouvert n'a été divulgué, et les participations dérivées directes de M. Chodakewitz après la transaction s'élèvent à 10 520 options. Le dépôt reflète une attribution standard liée à la rémunération plutôt qu'un changement dans l'exposition économique du directeur aux actions ordinaires en circulation.

Praxis Precision Medicines, Inc. (PRAX) meldete eine routinemäßige Insider-Aktienzuteilung durch ein am 27. Juni 2025 eingereichtes Formular 4. Direktor Jeffrey Chodakewitz erhielt am 26. Juni 2025 eine Zuteilung von 10.520 Aktienoptionen zum Ausübungspreis von 44,04 $ pro Aktie. Die Optionen werden in 12 gleichen monatlichen Raten über ein Jahr ab dem Zuteilungsdatum unverfallbar und laufen am 26. Juni 2035 ab. Es wurden keine Käufe oder Verkäufe von Stammaktien am offenen Markt gemeldet, und Herr Chodakewitz hält nach der Transaktion insgesamt 10.520 Optionen. Die Meldung stellt eine standardmäßige, vergütungsbezogene Zuteilung dar und keine Änderung der wirtschaftlichen Beteiligung des Direktors an den ausstehenden Stammaktien.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chodakewitz Jeffrey

(Last) (First) (Middle)
C/O PRAXIS PRECISION MEDICINES, INC.
99 HIGH STREET, 30TH FLOOR

(Street)
BOSTON MA 02110

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $44.04 06/26/2025 A 10,520 (1) 06/26/2035 Common Stock 10,520 $0 10,520 D
Explanation of Responses:
1. The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025.
Remarks:
/s/ Alex Nemiroff, as Attorney-in-Fact 06/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Praxis Precision Medicines (PRAX) stock options were granted in this Form 4?

The director received 10,520 stock options.

What is the exercise price of the PRAX options granted to Jeffrey Chodakewitz?

The exercise price is $44.04 per share.

When do the PRAX options begin vesting and over what period?

They vest in 12 equal monthly installments starting on 26 June 2025.

What is the expiration date of the granted PRAX stock options?

The options expire on 26 June 2035.

Did the Form 4 report any open-market purchases or sales of PRAX common stock?

No, the filing only reported an option grant; no shares were bought or sold.
Praxis Precision Medicines, Inc.

NASDAQ:PRAX

PRAX Rankings

PRAX Latest News

PRAX Latest SEC Filings

PRAX Stock Data

882.59M
19.34M
0.46%
108.65%
9.03%
Biotechnology
Pharmaceutical Preparations
United States
BOSTON